Kidney Disease

 
Kidney Week: Dapagliflozin Renoprotective, Cardioprotective in CKD Patients
October 26, 2020

Dapagliflozin is renoprotective and cardioprotective in chronic kidney disease patients, suggests a secondary analysis of the DAPA-CKD trial presented at Kidney Week 2020.